B6.129-Pou4f3^tm1.1Nat/J

Stock number: 010560
Research areas: Neurobiology Research, Research Tools

Description

These mice possess loxP sites on either side of the Pou4f3 (POU domain, class 4, transcription factor 3) coding region followed by an alkaline phosphatase reporter. When crossed with a cre recombinase-expressing strain, the offspring express AP in the retina, dorsal root ganglia, and other cells/tissues.

Detailed description

These mice possess loxP sites on either side of the Pou4f3 (POU domain, class 4, transcription factor 3) coding region followed by an alkaline phosphatase (AP) reporter. Mice that are homozygous for this floxed allele are viable, fertile, normal in size and do not display any gross physical or behavioral abnormalities. When crossed with a cre recombinase-expressing strain, the offspring express AP in the retina, dorsal root ganglia, and other cells/tissues.

Development

A loxP site was introduced to the 5' UTR (50 bp upstream of the ATG start codon), and three repeats of the SV40 early terminator were placed in the 3' UTR (300 bp downstream of the stop codon) along with a second loxP site, the human placental alkaline phosphatase (AP) gene, and an FRT-flanked neomycin resistance gene. The targeting vector was introduced to 129-derived embryonic stem cells. The neomycin cassette was excised with a germline FLP recombinase. This line was backcrossed six times to C57BL/6 by the donating laboratory.

Allele

Symbol: Pou4f3^tm1.1Nat
Name: targeted mutation 1.1, Jeremy Nathans
MGI accession ID: MGI:3849065
Generation method: Targeted
Attributes: Conditional ready (e.g. floxed); Reporter; No functional change
Marker symbol: Pou4f3
Marker name: POU domain, class 4, transcription factor 3
Chromosome: 18
Strain of origin: 129
Expressed genes: ALPP,alkaline phosphatase, placental,human
Molecular note: A loxP site was introduced to the 5' UTR (50 bp upstream of the ATG start codon), and three repeats of the SV40 early terminator were placed in the 3' UTR (300 bp downstream of the stop codon) along with a second loxP site, the human placental alkaline phosphatase (AP) gene, and an FRT-flanked neomycin resistance gene. The targeting vector was introduced to 129-derived embryonic stem cells. The neomycin cassette was excised with a germline FLP recombinase.